Clinical Trial Update: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing YK-029A to platinum-based chemotherapy as first-line treatment for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• YK-029A

Snippet

Sponsor: Suzhou Puhe Pharmaceutical Technology Co., LTD | Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: NOT_YET_RECRUITING